Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Amalgamated Bank

Amalgamated Bank lessened its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 118,506 shares of the medical research company’s stock after selling 1,248 shares during the quarter. Amalgamated Bank’s holdings in Edwards Lifesciences were worth $8,773,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Prasad Wealth Partners LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at about $277,000. BankPlus Trust Department purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $844,000. Impax Asset Management Group plc lifted its holdings in shares of Edwards Lifesciences by 34.6% in the 4th quarter. Impax Asset Management Group plc now owns 17,448 shares of the medical research company’s stock worth $1,292,000 after acquiring an additional 4,484 shares during the last quarter. W.G. Shaheen & Associates DBA Whitney & Co boosted its position in shares of Edwards Lifesciences by 45.9% during the 4th quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 161,221 shares of the medical research company’s stock worth $11,935,000 after purchasing an additional 50,744 shares during the period. Finally, Rothschild Investment LLC increased its holdings in Edwards Lifesciences by 2.1% in the 4th quarter. Rothschild Investment LLC now owns 12,981 shares of the medical research company’s stock valued at $961,000 after purchasing an additional 263 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on EW. Truist Financial restated a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Piper Sandler increased their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Evercore ISI dropped their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Barclays boosted their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group raised their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $79.95.

Insider Activity

In other news, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 26,489 shares of company stock valued at $2,002,829. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 1.8 %

EW stock opened at $71.46 on Wednesday. The company’s 50 day moving average is $72.78 and its two-hundred day moving average is $70.18. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $42.15 billion, a P/E ratio of 10.25, a PEG ratio of 4.82 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.